Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis

被引:15
作者
Behnes, Michaet [1 ]
Brueckmann, Martina [1 ]
Liebe, Volker [1 ]
Liebetrau, Claudia [1 ]
Lang, Siegfried [1 ]
Putensen, Christian [2 ]
Borggrefe, Martin [1 ]
Hoffmann, Ursula [1 ]
机构
[1] Univ Heidelberg, Fac Med Mannheim, Dept Med 1, D-68167 Mannheim, Germany
[2] Univ Bonn, Dept Anesthesiol, D-53127 Bonn, Germany
关键词
Drotrecogin alpha (activated); Oxidative stress; Oxidized low-density lipoprotein; Sepsis;
D O I
10.1016/j.jcrc.2008.09.002
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: It was hypothesized that the inflammatory response of patients with severe sepsis may result in changes of plasma levels of oxidized low-density lipoproteins (ox-LDLs) and that drotrecogin (activated) (DAA) (Xigris, Eli Lilly and Company [Indiana 46285, USA]) may. influence ox-LDL levels. Materials and Methods: The ox-LDL Levels were measured in severe septic patients on day 1, 4, and 7 of severe sepsis. Patients were treated either with Or Without DAA. Results: The ox-LDL levels increased significantly (P < .05) front day 1 to day 7 (day 1, mean +/- SEM, 25.4 +/- 1.8 U/L; day 4, mean +/- SEM, 34.3 +/- 2.1 U/L; day 7, mean +/- SEM, 38.3 +/- 2.1 U/L) in all patients (n = 68). The ox-LDL levels increased significantly from day 1 to day 7 both in patients treated with (n = 31) and without DAA (n = 37) (P < .001) (DAA-group; day 1, mean +/- SEM, 24.4 +/- 2.8 U/L; day 4, mean +/- SEM, 35.5 +/- 2.9 U/L; day 7, mean +/- SEM, 40.7 +/- 3.2 U/L) (Control group; day 1, mean +/- SEM, 26.3 +/- 2.8 U/L; day 4, mean SEM, 33.2 +/- 2.9 U/L; day 7, mean +/- SEM 36.4 +/- 2.9 U/L). No significant differences of ox-LDL levels were observed between both groups at any point of time (P > .05). Conclusions: The ox-LDL concentrations increase significantly during the first week of severe sepsis and are not affected by administration of drotrecogin alpha (activated) (Xigris). (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:537 / 541
页数:5
相关论文
共 29 条
  • [1] Efficacy and safety of recombinant human activated protein C for severe sepsis.
    Bernard, GR
    Vincent, JL
    Laterre, P
    LaRosa, SP
    Dhainaut, JF
    Lopez-Rodriguez, A
    Steingrub, JS
    Garber, GE
    Helterbrand, JD
    Ely, EW
    Fisher, CJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) : 699 - 709
  • [2] Anti-inflammatory properties of lipid oxidation products
    Bochkov, VN
    Leitinger, N
    [J]. JOURNAL OF MOLECULAR MEDICINE-JMM, 2003, 81 (10): : 613 - 626
  • [3] Sepsis: A new hypothesis for pathogenesis of the disease process
    Bone, RC
    Grodzin, CJ
    Balk, RA
    [J]. CHEST, 1997, 112 (01) : 235 - 243
  • [4] BONE RC, 1992, AM COLL CHEST PHYS S, V101, P1644
  • [5] Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective
    Cheng, T
    Liu, D
    Griffin, JH
    Fernández, JA
    Castellino, F
    Rosen, ED
    Fukudome, K
    Zlokovic, BV
    [J]. NATURE MEDICINE, 2003, 9 (03) : 338 - 342
  • [6] Plasma redox status relates to severity in critically ill patients
    de Vega, JMA
    Díaz, J
    Serrano, E
    Carbonell, LF
    [J]. CRITICAL CARE MEDICINE, 2000, 28 (06) : 1812 - 1814
  • [7] Oxidative stress in critically ill patients with systemic inflammatory response syndrome
    de Vega, JMA
    Díaz, J
    Serrano, E
    Carbonell, LF
    [J]. CRITICAL CARE MEDICINE, 2002, 30 (08) : 1782 - 1786
  • [8] Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure
    Dhainaut, JF
    Shorr, AF
    Macias, WL
    Kollef, MJ
    Levi, M
    Reinhart, K
    Nelson, DR
    [J]. CRITICAL CARE MEDICINE, 2005, 33 (02) : 341 - 348
  • [9] Role of oxidative stress in cardiovascular diseases
    Dhalla, NS
    Temsah, RM
    Netticadan, T
    [J]. JOURNAL OF HYPERTENSION, 2000, 18 (06) : 655 - 673
  • [10] Dimmeler S, 1997, CIRCULATION, V95, P1760